CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells

Full article: B7-H3-targeted CAR-T cell therapy for solid tumors

Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy

CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells and Correlates with Clinical Outcome

New molecule uses PD-1 to supply IL-2 to reactive T cells

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T- Cell Therapy in Treating B-Cell Hematological Malignancies - Danni Xie, Xin Jin, Rui Sun, Meng Zhang, Jiaxi Wang, Xia Xiong, Xiaomei Zhang, Mingfeng

Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

PDF] Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response

Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and

Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy

Spermidine promotes Nb CAR-T cells cytotoxicity

PDF] Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies - ScienceDirect

CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells and Correlates with Clinical Outcome

Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors